ImmunityBio Secures Five U.S. Patents for Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 51 minutes ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Patent Portfolio Strengthening: ImmunityBio has secured five U.S. patents covering the combination of IL-15 receptor agonist ANKTIVA with BCG for treating non-muscle invasive bladder cancer, with patent terms extending through 2035, ensuring the company's competitive edge in this market.
- Method of Treatment Protection: The patents include methods for treating BCG-naïve patients and a two-vial commercial kit, further solidifying the intellectual property position of the ANKTIVA and BCG combination, supporting the company's commercialization efforts in BCG-unresponsive bladder cancer.
- Clinical Trial Support: The patent portfolio aligns with ImmunityBio's exclusive supply agreement with Japan BCG Laboratory, backed by positive results from SWOG S1602 demonstrating the non-inferiority of Tokyo-172 BCG in high-grade recurrence-free survival, enhancing the company's supply capabilities in the U.S. market.
- Optimistic Market Outlook: The company anticipates that the combination of ANKTIVA and BCG will become the standard of care for this disease in the coming years, coupled with a 700% year-over-year revenue growth, indicating strong market expansion potential and clinical application prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.150
Low
5.00
Averages
7.33
High
9.00
Current: 8.150
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
See More
ImmunityBio Secures Five U.S. Patents for Cancer Treatment
- Patent Portfolio Strengthening: ImmunityBio has secured five U.S. patents covering the combination of IL-15 receptor agonist ANKTIVA with BCG for treating non-muscle invasive bladder cancer, with patent terms extending through 2035, ensuring the company's competitive edge in this market.
- Method of Treatment Protection: The patents include methods for treating BCG-naïve patients and a two-vial commercial kit, further solidifying the intellectual property position of the ANKTIVA and BCG combination, supporting the company's commercialization efforts in BCG-unresponsive bladder cancer.
- Clinical Trial Support: The patent portfolio aligns with ImmunityBio's exclusive supply agreement with Japan BCG Laboratory, backed by positive results from SWOG S1602 demonstrating the non-inferiority of Tokyo-172 BCG in high-grade recurrence-free survival, enhancing the company's supply capabilities in the U.S. market.
- Optimistic Market Outlook: The company anticipates that the combination of ANKTIVA and BCG will become the standard of care for this disease in the coming years, coupled with a 700% year-over-year revenue growth, indicating strong market expansion potential and clinical application prospects.
See More
Trump Intensifies Warnings to Iran, Crude Prices Surge
- Crude Price Surge: Following President Trump's stern warnings to Iran, crude oil prices approached two-week highs, indicating market sensitivity to geopolitical risks that could lead to increased energy costs and impact the global economy.
- Military Meeting Scheduled: Trump is expected to hold a Situation Room meeting on Tuesday to discuss military options regarding Iran, a move that may heighten market uncertainty and affect investor confidence and stock performance.
- U.S.-China Trade Agreements: Following a meeting between Trump and President Xi Jinping, multiple trade deals were announced, including China agreeing to purchase $17 billion in U.S. agricultural goods annually, which could help ease trade tensions and potentially boost related sectors.
- Market Pressure: U.S. stock futures faced pressure after a record-setting week, with S&P 500 and Nasdaq futures declining, reflecting investor caution ahead of the earnings season and ongoing geopolitical tensions.
See More
US Stock Futures Decline as Oil Prices Rise Amid Iran Tensions
- Cautious Market Sentiment: US stock futures declined in overnight trading on Sunday, with Dow futures down 0.79%, S&P 500 futures down 0.70%, and Nasdaq 100 futures down 0.93%, reflecting investor concerns over renewed tensions in the Middle East following President Trump's remarks on Iran.
- Rising Oil Prices: Brent crude futures rose approximately 2.21% to $111.67 per barrel, while WTI crude futures increased by 2.83% to $108.40 per barrel, indicating heightened fears of disruptions to global oil supplies amid geopolitical tensions.
- Bond Yields Surge: The benchmark 10-year Treasury yield remained elevated at 4.629% following hotter-than-expected US inflation data, with economists noting that G7 government bond yields have surged to their highest levels in over 20 years, reflecting market reactions to rising oil prices and fiscal deficits.
- Asian Markets Decline: Asian markets opened lower on Monday, with the KOSPI, Nikkei 225, and SSE Composite Index all declining, illustrating the global market's response to the escalating tensions between the US and Iran.
See More
Class Action Filed Against ImmunityBio, Inc. for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased the company's securities between January 19 and March 24, 2026, reflecting investor concerns over potential financial losses.
- Allegations of False Statements: The complaint alleges that the defendants materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, which could have serious implications for investors' trust and financial outcomes.
- Investor Action Deadline: Investors must request to be appointed as lead plaintiff by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the urgency and significance of investor participation in the legal process.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, meaning they only charge fees if they successfully recover funds, which reduces legal risks for investors and encourages more victims to join the lawsuit.
See More
ImmunityBio Secures Exclusive U.S. Rights for Bladder Cancer Therapy
- Licensing Agreement: ImmunityBio has secured a licensing deal with Japan BCG Laboratory to acquire exclusive U.S. rights for the bladder cancer treatment Bacillus Calmette-Guerin (BCG), marking a strategic expansion in the oncology sector.
- Clinical Trial Results: The Phase 3 trial results from February indicated that Tokyo strain BCG is non-inferior to FDA-approved TICE BCG in treating BCG-naïve high-grade non-muscle-invasive bladder cancer, enhancing the therapy's market potential.
- Market Expansion: Currently, ImmunityBio markets its immunotherapy Anktiva in the U.S. and plans to integrate the Tokyo strain BCG into its product offerings, which is expected to bolster the company's competitive position in the bladder cancer treatment market.
- Regulatory Submission Plans: As part of the agreement, ImmunityBio will file regulatory submissions to seek FDA approval and commercialization of the Tokyo strain BCG, demonstrating the company's commitment to new therapies and its intent to expand in the U.S. market.
See More
ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
See More
ImmunityBio Secures Five U.S. Patents for Cancer Treatment
- Patent Portfolio Strengthening: ImmunityBio has secured five U.S. patents covering the combination of IL-15 receptor agonist ANKTIVA with BCG for treating non-muscle invasive bladder cancer, with patent terms extending through 2035, ensuring the company's competitive edge in this market.
- Method of Treatment Protection: The patents include methods for treating BCG-naïve patients and a two-vial commercial kit, further solidifying the intellectual property position of the ANKTIVA and BCG combination, supporting the company's commercialization efforts in BCG-unresponsive bladder cancer.
- Clinical Trial Support: The patent portfolio aligns with ImmunityBio's exclusive supply agreement with Japan BCG Laboratory, backed by positive results from SWOG S1602 demonstrating the non-inferiority of Tokyo-172 BCG in high-grade recurrence-free survival, enhancing the company's supply capabilities in the U.S. market.
- Optimistic Market Outlook: The company anticipates that the combination of ANKTIVA and BCG will become the standard of care for this disease in the coming years, coupled with a 700% year-over-year revenue growth, indicating strong market expansion potential and clinical application prospects.
See More
Trump Intensifies Warnings to Iran, Crude Prices Surge
- Crude Price Surge: Following President Trump's stern warnings to Iran, crude oil prices approached two-week highs, indicating market sensitivity to geopolitical risks that could lead to increased energy costs and impact the global economy.
- Military Meeting Scheduled: Trump is expected to hold a Situation Room meeting on Tuesday to discuss military options regarding Iran, a move that may heighten market uncertainty and affect investor confidence and stock performance.
- U.S.-China Trade Agreements: Following a meeting between Trump and President Xi Jinping, multiple trade deals were announced, including China agreeing to purchase $17 billion in U.S. agricultural goods annually, which could help ease trade tensions and potentially boost related sectors.
- Market Pressure: U.S. stock futures faced pressure after a record-setting week, with S&P 500 and Nasdaq futures declining, reflecting investor caution ahead of the earnings season and ongoing geopolitical tensions.
See More
US Stock Futures Decline as Oil Prices Rise Amid Iran Tensions
- Cautious Market Sentiment: US stock futures declined in overnight trading on Sunday, with Dow futures down 0.79%, S&P 500 futures down 0.70%, and Nasdaq 100 futures down 0.93%, reflecting investor concerns over renewed tensions in the Middle East following President Trump's remarks on Iran.
- Rising Oil Prices: Brent crude futures rose approximately 2.21% to $111.67 per barrel, while WTI crude futures increased by 2.83% to $108.40 per barrel, indicating heightened fears of disruptions to global oil supplies amid geopolitical tensions.
- Bond Yields Surge: The benchmark 10-year Treasury yield remained elevated at 4.629% following hotter-than-expected US inflation data, with economists noting that G7 government bond yields have surged to their highest levels in over 20 years, reflecting market reactions to rising oil prices and fiscal deficits.
- Asian Markets Decline: Asian markets opened lower on Monday, with the KOSPI, Nikkei 225, and SSE Composite Index all declining, illustrating the global market's response to the escalating tensions between the US and Iran.
See More
Class Action Filed Against ImmunityBio, Inc. for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased the company's securities between January 19 and March 24, 2026, reflecting investor concerns over potential financial losses.
- Allegations of False Statements: The complaint alleges that the defendants materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, which could have serious implications for investors' trust and financial outcomes.
- Investor Action Deadline: Investors must request to be appointed as lead plaintiff by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the urgency and significance of investor participation in the legal process.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, meaning they only charge fees if they successfully recover funds, which reduces legal risks for investors and encourages more victims to join the lawsuit.
See More
ImmunityBio Secures Exclusive U.S. Rights for Bladder Cancer Therapy
- Licensing Agreement: ImmunityBio has secured a licensing deal with Japan BCG Laboratory to acquire exclusive U.S. rights for the bladder cancer treatment Bacillus Calmette-Guerin (BCG), marking a strategic expansion in the oncology sector.
- Clinical Trial Results: The Phase 3 trial results from February indicated that Tokyo strain BCG is non-inferior to FDA-approved TICE BCG in treating BCG-naïve high-grade non-muscle-invasive bladder cancer, enhancing the therapy's market potential.
- Market Expansion: Currently, ImmunityBio markets its immunotherapy Anktiva in the U.S. and plans to integrate the Tokyo strain BCG into its product offerings, which is expected to bolster the company's competitive position in the bladder cancer treatment market.
- Regulatory Submission Plans: As part of the agreement, ImmunityBio will file regulatory submissions to seek FDA approval and commercialization of the Tokyo strain BCG, demonstrating the company's commitment to new therapies and its intent to expand in the U.S. market.
See More
